GANX
Income statement / Annual
Last year (2023), Gain Therapeutics, Inc.'s total revenue was $55,180.00,
a decrease of 60.62% from the previous year.
In 2023, Gain Therapeutics, Inc.'s net income was -$22.27 M.
See Gain Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$55,180.00
|
$140,108.00
|
$164,994.00
|
$28,881.00
|
$41,301.00
|
$20,609.00
|
| Cost of Revenue |
$11.38 M |
$64,168.00 |
$7.16 M |
$2.26 M |
$0.00 |
$0.00 |
| Gross Profit |
-$11.32 M |
$75,940.00 |
-$7.00 M |
-$2.23 M |
$41,301.00 |
$20,609.00 |
| Gross Profit Ratio |
-205.22 |
0.54 |
-42.42 |
-77.22 |
1 |
1 |
| Research and Development
Expenses |
$11.52 M
|
$8.38 M
|
$7.16 M
|
$2.26 M
|
$1.59 M
|
$826,880.00
|
| General & Administrative
Expenses |
$10.79 M
|
$9.54 M
|
$6.83 M
|
$1.25 M
|
$555,165.00
|
$222,047.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.79 M
|
$9.54 M
|
$6.83 M
|
$1.25 M
|
$555,165.00
|
$222,047.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$22.31 M |
$17.92 M |
$13.99 M |
$3.51 M |
$2.14 M |
$1.05 M |
| Cost And Expenses |
$22.31 M |
$17.92 M |
$13.99 M |
$3.51 M |
$2.14 M |
$1.05 M |
| Interest Income |
$494,234.00 |
$375,357.00 |
$12,495.00 |
$3,637.00 |
$20,540.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$20,540.00 |
$0.00 |
| Depreciation &
Amortization |
$83,579.00
|
$64,168.00
|
$15,484.00
|
$9,592.00
|
$2,571.00
|
$741.00
|
| EBITDA |
-$22.17 M
|
-$17.78 M
|
-$13.82 M
|
-$3.47 M
|
-$2.10 M
|
-$1.03 M
|
| EBITDA Ratio |
-401.77 |
-126.2 |
-83.36 |
-116.8 |
-49.2 |
-49.13 |
| Operating Income Ratio
|
-403.28
|
-126.88
|
-83.8
|
-120.48
|
-50.85
|
-49.9
|
| Total Other
Income/Expenses Net |
$64,888.00
|
$279,283.00
|
-$60,425.00
|
-$92,847.00
|
-$86,222.00
|
-$67,441.00
|
| Income Before Tax |
-$22.19 M |
-$17.50 M |
-$13.89 M |
-$3.57 M |
-$2.19 M |
-$1.10 M |
| Income Before Tax Ratio
|
-402.11
|
-124.89
|
-84.16
|
-123.69
|
-52.94
|
-53.17
|
| Income Tax Expense |
$79,275.00 |
$92,976.00 |
$4,008.00 |
$5,386.00 |
$7,114.00 |
$9,781.00 |
| Net Income |
-$22.27 M |
-$17.59 M |
-$13.89 M |
-$3.58 M |
-$2.19 M |
-$1.11 M |
| Net Income Ratio |
-403.54 |
-125.55 |
-84.19 |
-123.88 |
-53.11 |
-53.64 |
| EPS |
-1.71 |
-1.48 |
-1.37 |
-0.3 |
-0.18 |
-0.19 |
| EPS Diluted |
-1.71 |
-1.48 |
-1.37 |
-0.3 |
-0.18 |
-0.19 |
| Weighted Average Shares
Out |
$13.01 M
|
$11.88 M
|
$10.17 M
|
$11.88 M
|
$11.88 M
|
$5.86 M
|
| Weighted Average Shares
Out Diluted |
$13.01 M
|
$11.88 M
|
$10.17 M
|
$11.88 M
|
$11.88 M
|
$5.86 M
|
| Link |
|
|
|
|
|
|
